Guardant Health
Researchers are planning a clinical trial after four metastatic FGFR2 fusion-positive pancreatic cancer patients responded to FGFR-directed therapy.
Liquid Biopsy Elucidates Resistance Mechanisms With Targeted Treatment Combo in EGFR-Mutated NSCLC
Premium
Analysis of ctDNA in the MARIPOSA trial showed fewer EGFR alterations and MET amplifications after Rybrevant-Lazcluze treatment than after Tagrisso.
Guardant Health Liquid Biopsy CDx Gets Japanese Regulatory Approval for Janssen Lung Cancer Drug
Patients with inoperable or recurrent NSCLC and EGFR exon 20 insertion mutations may be eligible for Janssen Pharmaceutical's amivantamab-vmjw.
Guardant Health's Shield Test Approved by FDA as Primary Blood-Based CRC Screening Option
The FDA followed the majority opinion of a previously convened advisory committee in approving the assay with cautions in its label regarding test limitations.
Guardant Health Colon Cancer Screening Test Backed by Majority Amidst Robust Debate in FDA Meeting
Premium
Committee members convened by the FDA to advise it on Guardant's application for premarket approval of its Shield assay ultimately voted in the test's favor.